Eosinophilic otitis media and comorbid asthma.
Journal
Current opinion in allergy and clinical immunology
ISSN: 1473-6322
Titre abrégé: Curr Opin Allergy Clin Immunol
Pays: United States
ID NLM: 100936359
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
pubmed:
17
9
2019
medline:
28
5
2021
entrez:
17
9
2019
Statut:
ppublish
Résumé
Eosinophilic otitis media (EOM) is an intractable otitis media characterized by numerous eosinophils infiltrating the middle ear cavity, which is part of the upper airway. EOM shows a high rate of comorbidity with asthma. They are considered to have a 'one airway, one disease' relationship. Here, we summarize our current knowledge regarding the characteristics of EOM, EOM's relationship with asthma and the efficacy of optimal treatments for EOM. The greater the severity of asthma, the more pronounced the development of EOM. Asthma control is usually inadequate in asthmatics who develop EOM, and appropriate strengthening of asthma inhalation therapy leads to improvement in the EOM. EOM severity can be divided into mild, moderate, and severe. Intratympanic infusion therapy using a topical steroid such as triamcinolone acetone is effective for mild EOM, whereas moderate EOM requires a systemic steroid in addition to triamcinolone acetone, and severe EOM forms granulation tissue that requires surgical removal. Recently, the effectiveness of molecularly targeted drugs is being reported, but more data need to be accumulated. EOM and asthma are closely related. Optimal asthma treatment is important for treating EOM. Treatments commensurate with the severity of EOM are being developed.
Identifiants
pubmed: 31524656
doi: 10.1097/ACI.0000000000000589
pii: 00130832-202002000-00003
doi:
Substances chimiques
Triamcinolone Acetonide
F446C597KA
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
9-13Références
Tomioka S, Yuasa R, Iino Y. Intractable otitis media in cases with bronchial asthma. Recent advances in otitis media. In: Mogi G, Honjo I, Ishii T, Takasaka T, editors. Proceedings of the Second Extraordinary Internation Symposium on Recent Advances in Otitis Media. Amsterdam, New York: Kugler Publications; 1993; 183–186.
Nagamine H, Iino Y, Kojima C, et al. Clinical characteristics of so called eosinophilic otitis media. Auris Nasus Larynx 2002; 29:19–28.
Lara-Sánchez H, Vallejo LA. Eosinophilic otitis media. N Engl J Med 2017; 376:e10.
Iino Y, Tomioka-Matsutani S, Matsubara A, et al. Diagnostic criteria of eosinophilic otitis media, a newly recognized middle ear disease. Auris Nasus Larynx 2011; 38:456–461.
Tanaka Y, Nonaka M, Yamamura Y, et al. Improvement of eosinophilic otitis media by optimized asthma treatment. Allergy Asthma Immunol Res 2013; 5:175–178.
Seo Y, Nonaka M, Tagaya E, et al. Eosinophilic otitis media is associated with asthma severity and smoking history. ORL J Otorhinolaryngol Relat Spec 2015; 77:1–9.
Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008; 63: (Suppl 86): 8–160.
Braunstahl GJ, Hellings PW. Allergic rhinitis and asthma: the link further unraveled. Curr Opin Pulm Med 2003; 9:46–51.
Pawankar R. Allergic rhinitis and asthma: are they manifestations of one syndrome? Clin Exp Allergy 2006; 36:1–4.
Incorvaia C, Masieri S, Cavaliere C, et al. Asthma associated to rhinitis. J Biol Regul Homeost Agents 2018; 32:s67–s71.
Iino Y. Eosinophilic otitis media: a new middle ear disease. Curr Allergy Asthma Rep 2008; 8:525–530.
Esu Y, Iino Y, Masuda M, et al. Proposal of a treatment strategy for eosinophilic otitis media based on middle ear condition. Otol Neurotol 2018; 39:e671–e678.
Nonaka M, Fukumoto A, Ozu C, et al. IL-5 and eotaxin levels in middle ear effusion and blood from asthmatics with otitis media with effusion. Acta Otolaryngol 2003; 123:383–387.
Iino Y, Kakizaki K, Katano H, et al. Eosinophil chemoattractants in the middle ear of patients with eosinophilic otitis media. Clin Exp Allergy 2005; 35:1370–1376.
Ohta N, Ishida A, Kurakami K, et al. Expressions and roles of periostin in otolaryngological diseases. Allergol Int 2014; 63:171–180.
Miura T, Matsubara A, Kudo N, et al. The expression of thymic stromal lymphopoietin in patients and animal models with eosinophilic otitis media. Acta Otolaryngol 2018; 138:447–451.
Iino Y, Usubuchi H, Kodama K, et al. Eosinophilic inflammation in the middle ear induces deterioration of bone-conduction hearing level in patients with eosinophilic otitis media. Otol Neurotol 2009; 31:100–104.
Ueki S, Ohta N, Takeda M, et al. Eosinophilic otitis media: the aftermath of eosinophil extracellular trap cell death. Curr Allergy Asthma Rep 2017; 17:33.
Iino Y, Kakizaki K, Saruya S, et al. Eustachian tube function in patients with eosinophilic otitis media associated with bronchial asthma evaluated by sonotubometry. Arch Otolaryngol Head Neck Surg 2006; 132:1109–1114.
Tokunaga T, Sakashita M, Haruna T, et al. Novel scoring system and algorithm for classifying chronic rhinosinusitis: the JESREC study. Allergy 2015; 70:995–1003.
Kanazawa H, Yoshida N, Hara M, et al. Risk factors for eosinophilic otitis media in patients with eosinophilic chronic rhinosinusitis. Int Adv Otol 2013; 9:353–358.
Haruna S, Yoshikawa M, Otori N, et al. Relationship between eosinophilic sinusitis and eosinophilic otitis media. Otol Rhino Laryngol Tokyo 2003; 46:472–480.
Global Initiative for Asthma. Global strategy for asthma management and prevention. Updated 2012.
Kanazawa H, Yoshida N, Yamamoto H, et al. Risk factors associated with severity of eosinophilic otitis media. Auris Nasus Larynx 2014; 41:513–517.
Hellings PW, Hessel EM, Van Den Oord JJ, et al. Eosinophilic rhinitis accompanies the development of lower airway inflammation and hyper-reactivity in sensitized mice exposed to aerosolized allergen. Clin Exp Allergy 2001; 31:782–790.
Wang J, Palmer K, Lŏtvall J, et al. Circulating, but not local lung, IL-5 is required for the development of antigen-induced airways eosinophilia. J Clin Invest 1998; 102:1132–1141.
Braunstahl GJ, Kleinjan A, Overbeek SE, et al. Segmental bronchial provocation induces nasal inflammation in allergic rhinitis patients. Am J Respir Crit Care Med 2000; 161:2051–2057.
Braunstahl GJ, Overbeek SE, Fokkens WJ, et al. Segmental bronchoprovocation in allergic rhinitis patients affects mast cell and basophil numbers in nasal and bronchial mucosa. Am J Respir Crit Care Med 2001; 164:858–865.
Beeh KM, Beier J, Kornmann O, et al. A single nasal allergen challenge increases induced sputum inflammatory markers in nonasthmatic subjects with seasonal allergic rhinitis: correlation with plasma interleukin-5. Clin Exp Allergy 2003; 33:475–482.
Greiff L, Andersson M, Svensson C, et al. Effects of orally inhaled budesonide in seasonal allergic rhinitis. Eur Respir J 1998; 11:1268–1273.
Seo Y, Nonaka M, Yamamura Y, et al. Optimal control of asthma improved eosinophilic otitis media. Asia Pac Allergy 2018; 8:e5.
Barnes PJ, Pedersen S. Efficacy and safety of inhaled corticosteroids in asthma. Report of a workshop held in Eze, France, October 1992. Am Rev Respir Dis 1993; 148 (4 Pt 2):S1–S26.
Iino Y, Nagamine H, Kakizaki K, et al. Effectiveness of instillation of triamcinolone acetonide into the middle ear for eosinophilic otitis media associated with bronchial asthma. Ann Allergy Asthma Immunol 2006; 97:761–766.
Global Initiative for Asthma. Global strategy for asthma management and prevention. Updated 2005.
Holgate S, Casale T, Wenzel S, et al. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 2005; 115:459–465.
Iino Y, Hara M, Hasegawa M, et al. Clinical efficacy of anti-IgE therapy for eosinophilic otitis media. Otol Neurotol 2012; 33:1218–1224.
Iino Y, Hara M, Hasegawa M, et al. Effect of omalizumab on biomarkers in middle ear effusion in patients with eosinophilic otitis media. Acta Otolaryngol 2014; 134:366–372.
Suzaki I, Kimura Y, Tanaka A, et al. Successful treatment of eosinophilic otitis media associated with severe bronchial asthma with an anti-IL-5 monoclonal antibody, mepolizumab. Auris Nasus Larynx 2019; 46:141–146.
Iino Y, Takahashi E, Ida S, et al. Clinical efficacy of anti-IL-5 monoclonal antibody mepolizumab in the treatment of eosinophilic otitis media. Auris Nasus Larynx 2019; 46:196–203.